MedTrace Logo

Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis

NCT01544894 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2012-09-03

No results posted yet for this study

Summary

The purpose of this study was to compare compliance and efficacy of raloxifene and strontium ranelate in a group of women with postmenopausal osteoporosis.

Conditions

  • Postmenopausal Osteoporosis
  • Compliance

Interventions

DRUG

Raloxifene

60 mg/d for one year

DRUG

Strontium ranelate

2 g/d, for one year

Sponsors & Collaborators

  • University of Valencia

    lead OTHER

Principal Investigators

  • Antonio Cano, MD · University of Valencia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01544894 on ClinicalTrials.gov